AEON Biopharma CEO Rob Bancroft gives a Botox history lesson.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/rOo-i...

AEON Biopharma CEO Rob Bancroft shares some of the tools the FDA is using to evaluate biosimilarity.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/zT65k...

AEON Biopharma CEO Rob Bancroft explains the financial difficulties therapeutic providers face when using Botox.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/GiXzo...

AEON Biopharma CEO Rob Bancroft discusses the FDA-requested bridging studies for the head to head trials between ABP-450 and Botox.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/v9fel...

AEON Biopharma CEO Rob Bancroft summarizes ABP-450's analytical studies and other work completed so far to support biosimilarity.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/m05Lt...

AEON Biopharma CEO Rob Bancroft underscores FDA feedback from Type 2a and 2b meetings.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/WzoC-...